Abingworth is a venture capital firm specializing in biotech and health tech companies at the Series B stage. Founded in 1973, the firm offers funding and expertise to turn scientific discoveries into effective medicines. Abingworth has supported over 180 companies, many of which have achieved successful mergers, acquisitions, or gone public. Notable investments include Nouscom. With offices in London, Menlo Park, and Boston, Abingworth became part of Carlyle in August 2022.
